Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. National Comprehensive Cancer Network. Small cell lung cancer: NCCN clinical practice guidelines (Version 2.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed 3 Mar 2021.
2. Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for eduction of chemotherapy-induced myelosuppression. Mol Cancer Ther. 2016;15(5):783–93.
3. Watkins T, Surowiecka MK, McCullough J. Transfusion indications for patients with cancer. Cancer Control. 2015;22(1):38–46.
4. Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–21.
5. Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–65.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献